GSK to develop biotech cancer drugs with SuperGen
GlaxoSmithKline could pay more than $375 million to co-develop cancer drugs with SuperGen based on epigenetic targets. SuperGen will receive $3 million in common stock investment upfront; GSK will have an option to further develop and globally commercialize compounds resulting from the collaboration.
Reuters | 10/26
This story published in BIO SmartBrief on 10/27/2009
More from SmartBrief:
Amgen to use ImmunoGen technology for cancer treatments
Thursday, September 17, 2009
Forma partners with Novartis in cancer-drug development
Thursday, July 30, 2009
Quintiles, Eisai to co-develop cancer drugs
Monday, November 9, 2009
Get stories like these delivered daily for FREE:
|
BIO SmartBrief
Designed specifically for biotechnology industry professionals like you, BIO SmartBrief is a FREE daily e-mail newsletter. It provides the latest news and information you need to stay informed about important biotech issues. Learn more |
|